Jia-Feng Wang1, Jin-Bao Li, Yan-Jun Zhao, Wen-Jing Yi, Jin-Jun Bian, Xiao-Jian Wan, Ke-Ming Zhu, Xiao-Ming Deng. 1. From the Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, China (J.-F.W., J.-B.L., W.-J.Y., J.-J.B., X.-J.W., K.-M.Z., X.-M.D.); and Department of Anesthesiology and Intensive Care, Shanghai Ninth People's Hospital, Shanghai Jiaotong University, Shanghai, China (Y.-J.Z.).
Abstract
BACKGROUND: Recent studies have shown that neutrophils may display an antigen-presenting function and inhibit lymphocyte proliferation by expressing programmed cell death 1 ligand 1 (PD-L1). The current study was performed to investigate the effect of neutrophils and their pathophysiological significance during sepsis. METHODS:Neutrophil PD-L1 expression was determined in both septic mice (n = 6) and patients (n = 41). Neutrophils from septic mice were subtyped into PD-L1 and PD-L1 populations to determine their phenotypes and functions. Septic neutrophils were cocultured with lymphocytes to observe the effect of septic neutrophils on lymphocyte apoptosis. RESULTS: The PD-L1 level on neutrophils from septic mice was significantly up-regulated (21.41 ± 4.76%). This level increased with the progression of sepsis and the migration of neutrophils from the bone marrow to the blood and peritoneal cavity. The percentages of CD11a, CD62L, and C-C chemokine receptor type 2 were lower, whereas the percentages of CD16 and CD64 were higher on PD-L1 neutrophils than on PD-L1 neutrophils. The migratory capacity of PD-L1 neutrophils was compromised. Septic neutrophils induced lymphocyte apoptosis via a contact mechanism, and this process could be reversed by anti-PD-L1 antibody. PD-L1 was also up-regulated on neutrophils from patients with severe sepsis (14.6% [3.75%, 42.1%]). The levels were negatively correlated with the monocyte human leukocyte antigen-DR level and positively correlated with the severity of septic patients. Neutrophil PD-L1 was a predictor for the prognosis of severe sepsis, with an area of 0.74 under the receiver operating curve. CONCLUSIONS: PD-L1 is up-regulated on neutrophils during sepsis, which may be related to sepsis-induced immunosuppression.
RCT Entities:
BACKGROUND: Recent studies have shown that neutrophils may display an antigen-presenting function and inhibit lymphocyte proliferation by expressing programmed cell death 1 ligand 1 (PD-L1). The current study was performed to investigate the effect of neutrophils and their pathophysiological significance during sepsis. METHODS: Neutrophil PD-L1 expression was determined in both septic mice (n = 6) and patients (n = 41). Neutrophils from septic mice were subtyped into PD-L1 and PD-L1 populations to determine their phenotypes and functions. Septic neutrophils were cocultured with lymphocytes to observe the effect of septic neutrophils on lymphocyte apoptosis. RESULTS: The PD-L1 level on neutrophils from septic mice was significantly up-regulated (21.41 ± 4.76%). This level increased with the progression of sepsis and the migration of neutrophils from the bone marrow to the blood and peritoneal cavity. The percentages of CD11a, CD62L, and C-C chemokine receptor type 2 were lower, whereas the percentages of CD16 and CD64 were higher on PD-L1 neutrophils than on PD-L1 neutrophils. The migratory capacity of PD-L1 neutrophils was compromised. Septic neutrophils induced lymphocyte apoptosis via a contact mechanism, and this process could be reversed by anti-PD-L1 antibody. PD-L1 was also up-regulated on neutrophils from patients with severe sepsis (14.6% [3.75%, 42.1%]). The levels were negatively correlated with the monocyte human leukocyte antigen-DR level and positively correlated with the severity of septic patients. Neutrophil PD-L1 was a predictor for the prognosis of severe sepsis, with an area of 0.74 under the receiver operating curve. CONCLUSIONS:PD-L1 is up-regulated on neutrophils during sepsis, which may be related to sepsis-induced immunosuppression.
Authors: Thomas Musich; Mohammad Arif Rahman; Venkatramanan Mohanram; Leia Miller-Novak; Thorsten Demberg; David J Venzon; Barbara K Felber; Genoveffa Franchini; George N Pavlakis; Marjorie Robert-Guroff Journal: J Immunol Date: 2018-09-14 Impact factor: 5.422
Authors: Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Derek C Angus; Lyle L Moldawer; Elliott D Crouser; Greg S Martin; Craig M Coopersmith; Scott Brakenridge; Florian B Mayr; Pauline K Park; June Ye; Ian M Catlett; Ihab G Girgis; Dennis M Grasela Journal: Crit Care Med Date: 2019-05 Impact factor: 7.598
Authors: Eleanor A Fallon; Bethany M Biron-Girard; Chun-Shiang Chung; Joanne Lomas-Neira; Daithi S Heffernan; Sean F Monaghan; Alfred Ayala Journal: J Leukoc Biol Date: 2018-02-02 Impact factor: 4.962
Authors: Andriani C Patera; Anne M Drewry; Katherine Chang; Evan R Beiter; Dale Osborne; Richard S Hotchkiss Journal: J Leukoc Biol Date: 2016-09-26 Impact factor: 4.962
Authors: Thomas Rimmelé; Didier Payen; Vincenzo Cantaluppi; John Marshall; Hernando Gomez; Alonso Gomez; Patrick Murray; John A Kellum Journal: Shock Date: 2016-03 Impact factor: 3.454
Authors: Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Elliott D Crouser; Greg S Martin; Timothy Albertson; Raquel R Bartz; Scott C Brakenridge; Matthew J Delano; Pauline K Park; Michael W Donnino; Mark Tidswell; Florian B Mayr; Derek C Angus; Craig M Coopersmith; Lyle L Moldawer; Ian M Catlett; Ihab G Girgis; June Ye; Dennis M Grasela Journal: Intensive Care Med Date: 2019-10-01 Impact factor: 17.440